Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

While the Gag/Pol responses did show a significant trend ( p = 0.047; χ 2 trend test) towards a higher positive rate with increasing dose of vaccine ( Table 2 ), these data should be viewed with caution given the low overall rate of Gag/Pol CTL responses.

also in 6,248 other papers